Latest news with #bioidenticalhormones
Yahoo
4 days ago
- Health
- Yahoo
Do you need HRT? Here's what the menopause doctors say
Asha turned 60 last year, but says she has the hormones of a 26-year-old. When she went through the menopause at 47, she felt 'dead from the neck down. My libido disappeared and I was plagued with hot flushes, night sweats and weight gain. Then a private menopause doctor prescribed me compounded bioidentical hormones to fit my exact profile and it changed my life…' Asha's experience is intriguing. As little as a decade ago, HRT – hormone replacement therapy – was pretty much out of the question. Studies in 2002 had linked it to breast cancer, and few women dared risk it. But it's had something of a renaissance in the last few years since dozens of studies have provided evidence that HRT may be safer than previously believed. Around 15 per cent of women aged 45 to 64 in England are currently prescribed HRT. But what of the women for whom HRT would be considered low-risk but don't take it – with so many long-term health benefits, are they missing out? Types of HRT What are the risks of HRT? What are the effects of stopping HRT? Benefits of HRT Side effects Finding a hormone replacement doctor Hormone replacement therapy is medication, taken in the form of tablets, gels, patches, sprays, creams and pessaries, that contains oestrogen that our bodies stop making during menopause. HRT's purpose is to tackle menopausal symptoms such as hot flushes, anxiety, low mood and vaginal discomfort. Your doctor will typically prescribe oestrogen along with progesterone or progestin (progesterone-like medication) to prevent growth of the lining of the uterus which increases the risk of endometrial cancer – unless you have had your uterus removed, in which case you'd take oestrogen on its own. A specialist doctor may also prescribe testosterone which can be effective at improving sexual wellbeing for postmenopausal women. You may benefit from HRT if you have: Moderate to severe hot flushes and night sweats Are experiencing uncomfortable vaginal symptoms Are at risk of osteoporosis Been through early menopause Oestrogen deficiency 'First and foremost, HRT is for women who are either within the normal menopause age range of 45-55, who have menopausal symptoms, or are under the age of 45 and going through an early menopause,' says Kathy Abernethy, a BMS menopause specialist and author of Menopause: The One Stop Guide. 'Then there are women who are post-menopause who have still got ongoing symptoms. For about 10 to 15 per cent of women, their symptoms will last into their 60s.' There are various different types of HRT. Depending on your age, health and family health history, it's essential to discuss the risks and which format is right for you with your GP or menopause doctor. Hormone replacement therapy is now available more cheaply thanks to a prescription prepayment certificate reducing a woman's HRT costs to less than £20 a year. HRT can be systemic, meaning the drug travels through your bloodstream, and this comes in the form of a pill, gel, spray or skin patch. These typically contain a higher dose of oestrogen than local HRT and can be used to treat any common menopause symptoms. This refers to vaginal oestrogen, which comes in cream, gel, pessary, or ring form, and is used to treat vaginal and urinary symptoms of menopause only. As it is a topical treatment, it minimises the amount of oestrogen absorbed by the body. As women become more prone to urinary tract infections with age, the use of vaginal oestrogen is highly recommended – especially if the risks associated with taking systemic HRT are putting you off, or it is too dangerous for you considering your health issues. 'It can be really beneficial – in fact most of us could be using vaginal oestrogen forever,' says Abernethy. The term 'bioidentical' refers to hormones in the HRT being chemically identical to those your body produces. It is sometimes referred to as 'body-identical', the difference being that body-identical HRT refers to regulated bioidentical hormones that have been the subject of numerous studies and are therefore deemed safer by experts. Some private clinics offer personalised compounded bioidentical HRT to women, after taking samples of their blood and saliva to make a bespoke formulation. Marketed as being 'more natural' than body-identical hormones, this is the type of custom-made hormone treatment taken by Asha at a cost of £400 every eight months. 'These are tailored to me, my health and my lifestyle, and it's the best money I've ever spent. I feel more vibrant, my skin looks better and I'm full of energy,' she says. However, experts consider compounded biodentical HRT a major concern, and the British Menopause Society (BMS) warns against it, stating 'cBHRT products are not recommended by the BMS. They are not evidence-based for effectiveness and safety'. Indeed, neither Dr Elise Dallas, a specialist in menopause care at The London General Practice, or Abernethy recommend cBHRT. 'A private clinic will tell you that it's made to measure just for you and has a little bit of oestrogen, of progesterone, of testosterone,' says Abernethy. 'The problem with that is it's not regulated, and we don't know the risks'. 'The term 'natural' in this context means the same as our own hormones,' says Abernethy. 'And that's exactly what conventional regulated bioidentical HRT does, mimicking what your body would have been producing during your reproductive years. In terms of HRT, we know that this seems to have fewer side effects and possibly fewer risks as well.' Apart from its contraceptive effects, the Mirena also provides the progestogen component of HRT, alongside oestrogen. A Mirena can minimise the unwanted effects of the PMS-type symptoms of the menopause. 'Although it's synthetic progesterone it releases so little and is very suitable for those that have might have bleeding problems at the end of their perimenopause,' says Dallas. According to the NHS, the risks of taking HRT include: Breast cancer Blood clots Stroke HRT can slightly increase the risk of breast cancer. If you've had breast cancer, you'll usually be advised not to take it. The increased risk is low: there are about five extra cases of breast cancer in every 1,000 women who take combined HRT for five years. But cancer risk from taking HRT depends on many different things, like the kind of HRT you take, your age and general health. The risk increases the longer you take it, and the older you are. It falls again after you stop taking it. There is little or no increase in the risk of breast cancer from oestrogen-only HRT, which you can take if you've had a hysterectomy to remove your womb. The safety of HRT can also depend on other things, such as fitness levels, body mass index and how soon during or after menopause you start taking it. Factor in a woman's family and personal medical history and her individual experience of menopausal symptoms, and it is clear that no one size fits all. 'Drinking more than 14 units a week, being sedentary and having a BMI over 30 are bigger risk factors for developing breast cancer than being on HRT,' says Dr Dallas. According to the NHS, HRT tablets can also slightly increase the risk of blood clots and stroke, but the risk is still very low and only applies to tablets, but not gels, sprays or patches. If you're already at risk of blood clots, you'll usually be advised to take HRT gels, sprays or patches. 'The fact is, we don't know if it's safe to take indefinitely, because we don't have the data for taking body identical HRT for 30 years,' says Dallas. 'So, all we can say is that so far, for at least five years there has been no increase in breast cancer cases [among those taking HRT]. However, the evidence is pointing towards it being way more beneficial than not taking it, although we would always counsel women on an individual basis.' This is why it is vital to keep having your health checks if you are on HRT. 'These are essential for looking at that person's individual risk and whether they are generally fit and healthy. If there are no other risks, there is so far no reason why someone cannot continue taking it until the grave,' says Dallas. 'There's no upper age at which you have to stop taking HRT, and there's no maximum duration. However, if you're on a combined HRT the risk of breast cancer, while small, increases with time,' says Abernethy. Menopausal symptoms can return, but furthermore it has an impact on long-term health conditions. 'As soon as you stop taking it, your bones go back to their postmenopausal condition without oestrogen, meaning a high risk of breakage. What's more, HRT is cardioprotective. Oestrogen is an anti-inflammatory, it prevents chronic inflammation and it's been shown that chronic inflammation stimulates all chronic diseases, whether it be heart disease or the beginning of cancers. So, taking that oestrogen away means losing that protection,' says Dallas. HRT has been found to be associated with a small reduction in the risk of bowel cancer. It can also reduce muscle loss that commonly occurs after the menopause and can improve strength. It gives a woman better bone, cardiovascular, brain and skin health compared with a woman that does not take it. 'Oestrogen is in every cell of our body, brains, hearts and bones, and it was found that heart attacks among women [who don't take HRT] increased five times after menopause, because we lack oestrogen. We're much more prone to osteoporosis and have a greater risk of brain disease once we lose our oestrogen protection. In many cases, the benefits of taking HRT outweigh the risks,' says Dallas. Common side effects of HRT include: Breast tenderness Muscle cramps Mood changes Headaches Nausea These symptoms should subside after a few weeks, as your body gets used to it. Vaginal bleeding or spotting is common with HRT, but if you bleed heavily or it continues after six months, discuss this with your GP. You may also experience itchy skin or a mild rash, which may mean you need a different treatment. Your GP can prescribe HRT. If you don't have a sympathetic doctor, it is a good idea to get focused support from an expert, especially if you have challenging symptoms. The BMS website can help you find your nearest menopause specialist. The only HRT you can get as an over-the-counter medication from a chemist is vaginal oestrogen, subject to a consultation with a pharmacist. Known as Gina, this comes in the form of vaginal tablets that are a locally acting oestrogen HRT used to treat the symptoms of vaginal atrophy after the menopause – eg, vaginal soreness and urinary tract infections. It's not uncommon for women to be turned away by their GP when they ask for HRT. If you have a history of blood clots, are prone to migraines, have high blood pressure or have a family history of breast cancer, you should discuss the options with a menopause specialist. You could also be turned away for being too old. If HRT is started within 10 years of the menopause or before the age of 60, it can protect you against osteoporosis and help prevent cardiovascular disease, as well as boosting your energy. If you start later than that, you may not get the same protection and there may be health risks. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Hormone Replacement Therapy Market Set to Grow at 6.48% CAGR Through 2030, Driven by Rising Demand
Hormone Replacement Therapy companies working in the market are Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others. (Albany, USA) DelveInsight's ' Hormone Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast–2030 ' report provides a comprehensive analysis of the global hormone replacement therapy (HRT) market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines market growth, offering historical and projected market sizes, revenue trends, and key factors driving the demand for HRT in managing hormonal imbalances. The report highlights the evolving landscape of hormone replacement therapies, exploring advancements in bioidentical hormones, transdermal delivery systems, and combination therapies that improve efficacy and patient compliance. It delves into how these innovations are enhancing treatment outcomes for conditions such as menopause, hypogonadism, thyroid disorders, and growth hormone deficiencies, providing safer and more personalized solutions. Additionally, the report evaluates the competitive landscape, profiling major players in the global HRT market while spotlighting emerging technologies and novel therapeutic approaches expected to drive future growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and recent product approvals, making it a vital resource for understanding the rapidly advancing field of hormone replacement therapy. Some of the key insights of the Hormone Replacement Therapy Market Report: The hormone replacement therapy market is projected to expand at a CAGR of 6.48% from 2024 to 2030. North America is estimated to hold a significant revenue share in the Hormone Replacement Therapy market. In September 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) recognized the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of locally advanced or metastatic ESCC and G/GEJ cancers with PD-L1 >1%. In August 2024, the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism, with the first U.S. supply expected in early 2025. In June 2024, Mangoceuticals announced the development of proprietary Oral Dissolvable Tablet (ODT) formulations of Enclomiphene Citrate, Pregnenolone, and DHEA to restore hormonal balance and naturally boost testosterone levels in men. In May 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval for VEOZAH (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product was the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage. Key players in the global Hormone Replacement Therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others. Hormone Replacement Therapy Overview Hormone Replacement Therapy (HRT) is a widely used treatment designed to replenish hormones that naturally decline due to aging or specific medical conditions. It is commonly prescribed for menopause-related symptoms in women, such as hot flashes, osteoporosis, and mood swings, as well as for hypogonadism and testosterone deficiency in men. Additionally, HRT plays a crucial role in managing conditions like hypothyroidism and growth hormone deficiencies. The therapy is available in various forms, including oral tablets, patches, injections, and topical gels, allowing personalized treatment approaches. Advancements in hormone formulations, including bioidentical and plant-derived hormones, have improved safety and efficacy, addressing concerns related to long-term use. Increasing awareness of hormonal imbalances and their impact on overall health is driving demand for HRT, making it a significant segment in the global healthcare market. Hormone Replacement Therapy Market Segment Analysis: The Hormone Replacement Therapy market report offers market segment analysis for the forecast period 2024-2030, segmented into: Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others) Hormone Replacement Therapy Market by Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others) Hormone Replacement Therapy Market by Route of Administration (Oral, Parenteral, and Transdermal) Hormone Replacement Therapy Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) Download the Hormone Replacement Therapy Market Analysis report for key market trends, innovations, and growth drivers. Hormone Replacement Therapy Market Dynamics One of the key factors driving the growth of the hormone replacement therapy market is the increasing awareness among women about managing menopausal symptoms. As women age, estrogen and progesterone levels decline significantly, leading to hormonal imbalances. In response, the pituitary gland increases follicle-stimulating hormone (FSH) production, causing symptoms such as hot flashes, excessive sweating, and palpitations. With a growing global population of women reaching menopause, the demand for hormone replacement therapy to manage these symptoms is expected to rise. Additionally, ongoing research and development efforts by key pharmaceutical companies are driving the discovery of novel treatments for hormonal imbalances. The increasing number of product approvals is further expanding the availability of hormone replacement therapies. Several companies are actively investing in the introduction of innovative therapies for conditions such as growth hormone deficiency and testosterone replacement, enhancing treatment options for both men and women. However, certain challenges may hinder market growth. The high costs associated with drug development, potential side effects linked to long-term hormone therapy use, and stringent regulatory approval processes remain significant barriers. Despite these challenges, the overall hormone replacement therapy market is expected to expand steadily, driven by advancements in treatment options and increasing patient awareness. North America Set to Lead the Growth of the Global Hormone Replacement Therapy Market North America is expected to dominate the hormone replacement therapy market, driven by the increasing demand for hormone replacement drugs among women due to the rising prevalence of menopausal-related issues. Additionally, the growing incidence of growth deficiencies, thyroid disorders, osteoporosis, and hypogonadism, along with active research and development efforts, is fueling market expansion in the region. The presence of key pharmaceutical companies, frequent product launches, and favorable reimbursement policies further support market growth. For instance, the increasing prevalence of thyroid-related conditions has led to a higher demand for hormone therapies, as these treatments play a crucial role in managing conditions like thyroid cancer and hormonal imbalances. Moreover, recent product relaunches and strategic collaborations among manufacturers are strengthening the market landscape. With these factors in play, North America is expected to maintain its leadership in the hormone replacement therapy market throughout the forecast period. Hormone Replacement Therapy Market Drivers Growing awareness of menopause-related health issues and a rising aging population are increasing the demand for HRT to manage symptoms like osteoporosis, cardiovascular risks, and hormonal imbalances. The development of safer, more effective hormone formulations, including bioidentical and plant-based options, has improved patient outcomes and increased adoption rates. Hormone Replacement Therapy Market Barriers Concerns about long-term HRT use, including increased risks of breast cancer, cardiovascular diseases, and stroke, limit patient adoption and regulatory approvals. The cost of HRT, especially newer formulations and customized therapies, can be a financial burden for patients, with limited insurance reimbursement restricting accessibility. To learn more about Hormone Replacement Therapy drivers and barriers, visit @ Hormone Replacement Therapy Competitive Landscape and Market Forecast Report Table of Contents 1. Hormone Replacement Therapy Market Report Introduction 2. Hormone Replacement Therapy Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Hormone Replacement Therapy Market Key Factors Analysis 6. Hormone Replacement Therapy Market Porter's Five Forces Analysis 7. Hormone Replacement Therapy Market Layout 8. Hormone Replacement Therapy Market Company and Product Profiles 9. KOL Views 10. Project Approach 11. About DelveInsight 12. Disclaimer & Contact Us About DelveInsight DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth. Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
